

Reissue \$

PATENT
Attorney Docket No. 2489.0028-12

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Reissue Application of:
U.S. Patent No. 5,658,911

Joseph T. STRUPCZEWSKI et al.

Reissue Serial No.: Unassigned

Filed: Herewith

For: HETEROARYLPIPERIDINES,
AND THEIR USE AS ANTIPSYCHOTICS
AND ANALGETICS

Group Art Unit: Unassigned

Examiner: Unassigned

REISSUE PATENT APPLICATION TRANSMITTAL

BOX REISSUE

Assistant Commissioner for Patents
Washington, D.C. 20231

APPLICATION FOR REISSUE OF:

☒ Utility Patent

☐ Design Patent

1. ☒ Fee Transmittal Form
2. ☒ Copy of printed Pat. No. 5,658,911, in double column format pursuant to 37 C.F.R. §1.173(a)(1)
3. ☐ Drawing(s) (proposed amendments, if appropriate)
4. ☒ Reissue Oath/Declaration (original copy)
(37 C.F.R. § 1.175)

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

5. Original U.S. Patent

☒ Consent of Assignee, Offer to Surrender Original Patent, and Statement Under 37 C.F.R. § 3.73(b)

or

☐ Ribbioned Original Patent

☐ Affidavit/Declaration of Loss

6. Original U.S. Patent currently assigned?

☒ Yes ☐ No

(If Yes, check applicable box(es))

☒ Written Consent of all Assignees

☒ 37 C.F.R. § 3.73(b) Statement

☒ Power of Attorney

7. ☐ Foreign Priority Claim (35 U.S.C. 119)

8. ☒ Information Disclosure Statement (IDS)/PTO 1449

☒ Copies of IDS Citations

9. ☐ English Translation of Reissue Oath/Declaration

10. ☐ Small Entity Statement(s)

☐ Statement filed in prior application, status still proper and desired

11. ☒ Preliminary Amendment

12. ☒ Also enclosed is: an Application Data Sheet pursuant to 37 C.F.R. §1.76

If there are any fees due under 37 C.F.R. §§ 1.16 or 1.17 which are not enclosed herewith, including any fees required for an extension of time under 37 C.F.R. § 1.136, please charge such fees to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.


By: Lara C. Kelley
Lara C. Kelley
Reg. No. 41,551

Dated: November 9, 2000

PATENT

Attorney Docket No. 2489.0028-12

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Reissue Application of:)
 U.S. Patent No. 5,658,911)
 Joseph T. STRUPCZEWSKI et al.)
 Reissue Serial No.: Unassigned)
 Reissue Application Filed: Herewith)
 For: HETEROARYLPIPERIDINES,)
 AND THEIR USE AS ANTIPSYCHOTICS)
 AND ANALGETICS)

Group Art Unit: Unassigned

Examiner: Unassigned

REISSUE APPLICATION FEE TRANSMITTAL FORM

BOX REISSUE
 Assistant Commissioner for Patents
 Washington, D.C. 20231

Claims as Filed - Part 1							
Claims in Patent	For	Number Filed In Reissue Application	(3) Number Extra	Small Entity		Other Than a Small Entity	
				Rate	Fee	Rate	Fee
(A) 45	Total Claims (37 CFR 1.16(j))	(B)	0 =	x\$ ____ =		or	x\$18 = ____
(C) 10	Independent Claims (37 CFR 1.16(i))	(D)	0 =	x\$ ____ =			x\$ 80 = ____
Basic Fee (37 CFR 1.16(h))					\$ ____	OR	\$ 710.00
Total Filing Fee					\$ ____		\$ 710.00

Claims as Amended - Part 2								
	(1) Claims Remaining After Amendment		(2) Highest Number Previously Paid For	(3) Extra Claims Present	Small Entity		Other Than a Small Entity	
					Rate	Fee		Rate Fee
Total Claims (37 CFR 1.16(j))	115	MINUS	45	= 70	x\$ _____ =		or	x\$ <u>18</u> = <u>\$1260.00</u>
Independent Claims (37 CFR 1.16(i))	19	MINUS	10	= 9	x\$ _____ =			x\$ <u>80</u> = <u>\$ 720.00</u>
Total Additional Fee						\$	OR	\$ <u>1980.00</u>

A check is enclosed for \$2690.00 to cover Basic Filing Fee and Additional Claims Fee.

If there are any fees due under 37 C.F.R. §§ 1.16 or 1.17 which are not enclosed herewith, including any fees required for an extension of time under 37 C.F.R. § 1.136, please charge such fees to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: Lara C. Kelley
Lara C. Kelley
Reg. No. 41,551

Dated: November 9, 2000

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000



PATENT

Attorney Docket No. 2489.0028-12

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue Application of:)	
U.S. Patent No. 5,658,911)	
Joseph T. STRUPCZEWSKI et al.)	Group Art Unit: Unassigned
Reissue Serial No.: Unassigned)	Examiner: Unassigned
Filed: Herewith)	
For: HETEROARYLPIPERIDINES,)	
AND THEIR USE AS ANTIPSYCHOTICS)	
AND ANALGETICS)	

BOX REISSUE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

**CONSENT OF ASSIGNEE, OFFER TO SURRENDER
ORIGINAL PATENT, AND STATEMENT UNDER 37 C.F.R. § 3.73(b)**

U.S. Patent No. 5,658,911 is assigned to Aventis Pharmaceuticals Inc. as assignee of the entire right, title and interest in said patent by virtue of an assignment recorded at Reel 8238, Frame 0759 on November 5, 1996, and by virtue of a change of name document recorded on February 8, 2000, at Reel 10567, Frame 0944.

Aventis Pharmaceuticals Inc. hereby consents to the accompanying application for reissue of U.S. Patent 5,658,911.

Aventis Pharmaceuticals Inc. hereby offers to surrender U.S. Patent 5,658,911, when the reissue application is otherwise in condition for allowance.


**Reissue Application of
Patent No. 5,658,911
Atty. Docket No. 2489.0028-12**

The undersigned, whose title is supplied below, is empowered to sign this document on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

September 21, 2000

Date


Signature

Stephen L. Nesbitt

Typed or printed name

Professional Development and Licensing
Support
Title